by AdoloreJTC24 | Jan 14, 2026 | Press Releases
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to hereditary neuronal sodium ion channel mutationsAdolore’s Kv7 voltage-gated potassium channel activating rdHSV-CA8* therapy is equipotent to...
by AdoloreJTC24 | Aug 12, 2025 | Press Releases
DELRAY BEACH, FL / ACCESS Newswire / August 12, 2025 / Adolore BioTherapeutics, Inc., (“Company” or “Adolore”) announced that Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of...
by AdoloreJTC24 | Jun 15, 2025 | Press Releases
Findings highlight the advantages of Adolore’s approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for...
by AdoloreJTC24 | Apr 23, 2025 | Press Releases
DELRAY BEACH, FL / ACCESS Newswire / April 23, 2025 / Adolore BioTherapeutics (“Adolore” or the “Company”) is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to...
by AdoloreJTC24 | Feb 4, 2025 | Press Releases
DELRAY BEACH, FL / ACCESS Newswire / February 4, 2025 / Adolore BioTherapeutics (“Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS...
by AdoloreJTC24 | Oct 2, 2024 | Press Releases
DELRAY BEACH, FL / October 2, 2024 / Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy C....